VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company with a proprietary blood-brain barrier platform delivery technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced a key...
Tailwinds' Take: This is excellent progress. If it translates into human data, a decent probability, it could be huge. Once they get properly funded and on Nasdaq, Bioasis should start to attract some real investor attention. We entered early...
Tailwinds' Take: Positive in that the timeline for development appears to be unchanged post the meeting, so that implies there were no significant issues from the FDA's side. How they fund this going forward remains a mystery to me....
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis TECHNOLOGIES, INC . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company with a proprietary blood-brain barrier platform technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced that Dr. Deborah...
Tailwinds' Take: The Company needed this cash infusion rather desperately. I believe that management participated in the transaction. The technology is solid, but they need to develop a long-term plan to fund Bioasis. GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (“Bioasis” or the...
Tailwinds' Take: this is a nice announcement, securing more IP around this platform technology. We remain intrigued by the Company, especially at this valuation, but would like to see a clearer path to financing before stepping up in a...
Quarterly earnings season is the four times each year in which companies give investors an inside look as to what's going on. They not only reveal their sales and profits, but, typically, they provide guidance (either specifically or in...
Tailwinds' Take: Obviously, this cash was needed and will not suffice them for long. We would like to see just how much director and management participation took place in this round. The next catalyst is an FDA meeting in...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain...
Tailwinds' Take: the closing of this private placement is a key catalyst for Bioasis shares. We have been adding in the Tailwinds portfolios and look forward to seeing how details concerning the level of insider participation. If insiders were...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.